Omeros (OMER) Tops Q3 EPS by 8c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. EXPE
5. ARM
6. QCOM
7. CPAY
8. DDOG
9. CHYM
10. PAYC

Go back to Omeros (OMER) Tops Q3 EPS by 8c, Revenues Beat

Omeros Corporation Reports Third Quarter 2019 Financial Results

November 12, 2019 4:02 PM EST

Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2019.

Third Quarter 2019 Financial Highlights

3Q 2019 revenues were $29.9 million, another quarter of record sales of OMIDRIA® (phenylephrine and... More